We claim:

1. A compound of the Formula 1:

Formula 1

wherein;

R₁ is selected from the group consisting of aryl, heteroaryl, cylcloalkyl and heterocycloalkyl;

wherein R_1 is optionally substituted with one or more substituents R_a ; wherein R_a is selected from the group consisting of alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, aryl, heteroaryl, aralkyl, heteroaralkyl and $-(R_7)_nNR_8R_9$

wherein R_7 is selected from alkyl, alkoxy, and oxyalkyl, R_8 and R_9 can be independently selected from H, and alkyl, or R_8 and R_9 can join together such that NR_8R_9 form a 5 or 6-member heterocyclic ring, and n is selected from 0, 1, 2 and 3)

wherein the substituents(s) R_a is optionally further substituted with one or more substituents are selected from the group consisting of alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, and $-(R_7)_nNR_8R_9$, wherein R_7 , R_8 , R_9 and n are as defined above, and

R₂ and R₃ are:

a) independently selected from the group consisting of H, alkyl,
aralkyl optionally substituted aryl, optionally substituted heteroaryl
and optionally substituted, saturated or unsaturated, 5-or 6-

DOCKET NO. 317743-122

membered, homocyclic or heterocyclic rings wherein the optional substituent may be selected from the group consisting of H, alkyl, alkoxy, and halo;

or

b) joined together to form a 3, 4, 5, 6 or 7 member spirocyclic ring, and

Ar₁ is aryl and;

Ar₁ is optionally substituted with one or more substituents R_b ; wherein R_b is selected from the group consisting of: alkyl, alkoxy, halo, haloalkyl, nitro, $-(R_7)_nNR_8R_9$, alkanoyl, aryl, heteroaryl, $-O(CH_2)_mNR_{10}R_{11}$ and $-SO_2-NR_{10}R_{11}$ (wherein R_7 is selected from alkyl, alkoxy; and oxyalkyl, R_8 and R_9 can be independently selected from H, and alkyl, or R_8 and R_9 can join together such that NR_8R_9 form a 5 or 6- member heterocyclic ring, and n is selected from 0, 1, 2 and 3) and the groups R_{10} and R_{11} can be independently selected from H, or alkyl, or groups R_{10} and R_{11} can join together such that NR_{10} R_{11} form a 5 or 6-member ring, and m is selected from 1, 2, 3, 4 and 5);

wherein the substituent(s) R_b are optionally further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro and -(R₇)_nNR₈R₉ (wherein R₇, R₈, R₉ and n are as described above).

wherein when Ar₁ is phenyl then

a) Ar₁ has a substituent R_b at the 2-position wherein the substituent is selected from the group consisting of nitro, haloalkyl, cyano, - $C(O)R_{12}$ - $C(O)OR_{12}$, - $C(O)NR_{12}R_{12}$, - $S(O)R_{12}$, - $S(O)_2R_{12}$, and - $S(O)_2NR_{12}R_{13}$ (wherein R₁₂ and R₁₃ are independently selected from H and alkyl)

DOCKET NO. 317743-122

or

b) Ar₁ has an alkanoyl substituent at the 4-position,

and a salt solvate or hydrate thereof.

- 2. A compound of claim 1 wherein Ar₁ is selected from the group consisting of phenyl and naphthyl.
- 3. A compound of claim 2 wherein Ar₁ is naphthyl.
- 4. A compound of claim 2 wherein Ar₁ is 4-acetylphenyl.
- 5. A compound of claim 2 wherein Ar_1 is phenyl, and there is a substituent R_b at the 2-position and R_b is selected from the group consisting of nitro, trifluoromethyl and $-SO_2-NR_{10}R_{11}$.
- 6. A compound of claim 5 wherein the substituent R_b at the 2-position is nitro.
- 7. A compound of claim 5 with a second substituent Rb at the 4-position selected from the group consisting of: methoxy; ethoxy; propoxy; O(CH₂) _mNR₁₀R₁₁ and acetyl.
- 8. A compound of claim 7 wherein Ar_1 is 2-nitro-4-methoxyphenyl.
- 9. A compound of claim 1 wherein R₁ is selected from the group consisting of: phenyl; naphthyl; tetrahydronaphthyl; and pyridyl.
- 10. A compound of claim 9 wherein R₁ is pyridyl.
- 11. A compound of claim 9 wherein R_1 is naphthyl or tetrahydronaphthyl.
- 12. A compound of claim 9 wherein R₁ is phenyl.
- 13. A compound of claim 12 wherein R₁ is substituted with one or more substituents R_a, wherein R_a is selected from the group consisting of: alkyl; alkoxy; halo; cyano; thioalkyl; nitro; alkanoyl; haloalkyl; acetyl; piperazinyl.
- 14. A compound of claim 13 wherein the substituent(s) R_a are independently selected from the group consisting of: methyl; ethyl; isopropyl; chloro; fluoro; trifluoromethyl; thiomethyl; cyano; nitro; methoxy and piperazinyl.
- 15. A compound of claim 14 wherein there is one substituent R_a.

- A compound of claim 15 wherein the substituent R_a is located at the 2position of the phenyl ring R₁.
- 17. A compound of claim 16 wherein R_a is methyl.
- 18. A compound of claim 14 wherein there are two substituents R_a.
- 19. A compound of claim 18 wherein the two substituents R_a are located at the 2-position and the 6-position.
- 20. A compound of claim 19 wherein one of the substituents R_a is methyl, and the second substituent R_a is selected from the group consisting of: methyl, and ethyl.
- 21. A compound of claim 20 wherein the second substituent R_a is methyl.
- 22. A compound as defined in claim 1 wherein R₂ and R₃ are independently selected from H, alkyl, aralkyl, and optionally substituted, saturated or unsaturated, 5 or 6-member homocyclic or heterocyclic rings; or R₂ and R₃ are joined together to form a 3, 5 or 6 member spirocyclic ring.
- 23. A compound as described in claim 22 wherein R₂ and R₃ are selected independently from H, methyl, isopropyl, t-Butyl, sec-Butyl, cyclohexyl, phenyl, benzyl, 3-thiophene.
- 24. A compound as described in claim 22 wherein R₂ and R₃ join together to form a 3, 5, or 6-member spirocyclic ring.
- 25. A compound from claim 1 selected from the group consisting of: N-(2-methylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (E4.3):
- N-(2,6-dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (E33.6);
- N-(2-methylphenyl)-2-[3-(2-nitrophenyl)-thioureido]-2-phenyl acetamide **(E4.2)** *N*-(2-methylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)-thioureido]-2-phenyl acetamide **(E4.4)**;
- N-(2,6-dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)-thioureido]-2-phenyl acetamide (E33.7);
- N-(2,6-dimethylphenyl)-2-[3-(4-N,N-dimethylaminoethoxy-2-trifluoromethylphenyl)-thioureido]-2-phenyl acetamide (E33.8);

N-(2-isopropyl-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (E28.1);

N-(2-chloro-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (E29.1);

N-(2,6-dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)-thioureido]-

4-methylpentanamide (E51.3);

N-(2,6-dimethylphenyl)-2-[3-(4-(2-N,N-dimethylamino)ethoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (E33.4);

(R)-N-(2,6-dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)

-thioureido]-4-methylpentanamide (E51.1*);

N-(2,6-dimethylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)-thioureido]-2-phenyl acetamide (E33.1);

N-(2,6-dimethylphenyl)-2-[3-(2-N,N-dimethylsulphonamidophenyl)-thioureido]-2-phenyl acetamide (E33.2);

N-(2,6-dimethylphenyl)-2-[3-(2-N-methylpiperizinylsulphonamidophenyl)-thioureido]-2-phenyl acetamide **(E33.3)**;

and N-(2,6-dimethylphenyl)-2-[3-(4-(2-N,N-dimethylamino)sulphonamide-2-nitro-thioureido]-2-phenyl acetamide (E33.5).

- 26. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- 27. A method for treating a patient having a medical condition for which a glycine transport inhibitor is indicated, comprising the step of administering to a patient a pharmaceutical composition as described in claim 26.
- A method according to claim 27 wherein the medical condition is pain or spasticity.